Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.54 |
| ▸ | MAPT | P10636 | 4/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.52 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.50 |
| ▸ | HTR1A | P08908 | 1/20 | 0.50 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.46 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.45 |
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | TNNI3 | P19429 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28353455 | 0.79 | TSHR (0.61) | HSD17B10MAPTMAPK1GAASMN1; SMN2 | |
| SCHEMBL28965465 | 0.79 | TSHR (0.61) | HSD17B10MAPTMAPK1GAASMN1; SMN2 | |
| SCHEMBL1280419 | 0.78 | ALDH1A1 (0.54) | GAASMN1; SMN2TSHRAPOBEC3AAPOBEC3G | |
| SCHEMBL29572812 | 0.78 | TSHR (0.43) | HSD17B10MAPTMAPK1GAASMN1; SMN2 | |
| SCHEMBL31056388 | 0.77 | NPC1 (0.57) | HSD17B10MAPTSMN1; SMN2TSHRAPOBEC3A | |
| SCHEMBL17185312 | 0.76 | APOBEC3A (0.61) | GAASMN1; SMN2TSHRAPOBEC3AAPOBEC3G | |
| SCHEMBL17331874 | 0.76 | ALDH1A1 (0.48) | HSD17B10MAPTMAPK1GAASMN1; SMN2 | |
| SCHEMBL9819255 | 0.75 | HSD17B10 (0.57) | HSD17B10MAPTMAPK1GAASMN1; SMN2 | |
| SCHEMBL14687884 | 0.75 | NPC1 (0.53) | HSD17B10MAPK1GAAALDH1A1PDE3B | |
| SCHEMBL4196712 | 0.75 | PKM (0.67) | HSD17B10MAPTTSHRALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8722662-B2 | Heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-05-13 | — | — | US | disclosed |
| US-20130267494-A1 | 1,4-OXAZEPANE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-10-10 | — | — | US | disclosed |
| CN-103261176-A | 1, 4-oxazepane derivatives | TAKAEDA CHEMICAL IND LTD | 2013-08-21 | — | — | CN | disclosed |
| EP-2625170-A1 | 1,4-OXAZEPANE DERIVATIVES | Takeda Pharmaceutical Company Limited (JP) | 2013-08-14 | — | — | EP | disclosed |
| US-20120088748-A1 | HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-12 | — | — | US | disclosed |
| WO-2012046882-A1 | 1,4-OXAZEPANE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130267494-A1 | 1,4-OXAZEPANE DERIVATIVES | MAOB, SLC6A4, SLC6A2 | HSD17B10 216/4885MAPT 2268/4885MAPK1 1253/4885 |
| US-20120088748-A1 | HETEROCYCLIC COMPOUNDS | SLC6A2, MAOB, MAOA | HSD17B10 424/4885MAPT 926/4885MAPK1 1107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.